menu
    • menu
    [{"orgOrder":0,"company":"Made Scientific","sponsor":"Tevogen Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Partnership","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Made Scientific \/ Tevogen Bio","highestDevelopmentStatusID":"5","companyTruncated":"Made Scientific \/ Tevogen Bio"},{"orgOrder":0,"company":"Made Scientific","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"HG-CT-1","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Made Scientific \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Made Scientific \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Made Scientific","sponsor":"Sentinel BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"SENT-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Made Scientific \/ Sentinel BioTherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Made Scientific \/ Sentinel BioTherapeutics"},{"orgOrder":0,"company":"Made Scientific","sponsor":"Cellergy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"CLG-001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Made Scientific \/ Cellergy Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Made Scientific \/ Cellergy Therapeutics"},{"orgOrder":0,"company":"Made Scientific","sponsor":"Cytora Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2026","type":"Collaboration","leadProduct":"hOMSC200","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Made Scientific \/ Made Scientific | ZEO ScientifiX","highestDevelopmentStatusID":"6","companyTruncated":"Made Scientific \/ Made Scientific | ZEO ScientifiX"}]

    Find Clinical Drug Pipeline Developments & Deals by Made Scientific

    Menu

    Made Scientific

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : hOMSC200

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Recipient : Cytora Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cytora, Made Scientific, and Zeo ScientifiX Partner to Manufacture Cytora's Stem Cell Therapy in US

                            Details : The collaboration aims to advance hOMSC200, a Cell & Gene Therapy, for non-healing Diabetic Foot Ulcers.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 07, 2026

                            Lead Product(s) : hOMSC200

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Recipient : Cytora Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLG-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : Cellergy Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Made and Cellergy Partner to Advance First-in-Human Mitochondrial Therapy

                            Details : As part of the partnership, CLG-001, a miscellaneous product, will be developed with an undisclosed target to address a key focus area.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 24, 2025

                            Lead Product(s) : CLG-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : Cellergy Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Hemogenyx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Made Scientific and Hemogenyx Announce Technology Transfer and Manufacturing Partnership

                            Details : The partnership aims to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 08, 2025

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Hemogenyx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENT-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sentinel BioTherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Made Scientific and Sentinel Announce Partnership to Advance ePP Encapsulated Cell Therapy

                            Details : Made Scientific is partnering with Sentinel BioTherapeutics to manufacture SENT-001, an allogeneic encapsulated cell therapy delivering IL-2 for solid tumor immunotherapy.

                            Product Name : SENT-001

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 15, 2025

                            Lead Product(s) : SENT-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sentinel BioTherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Made Scientific

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TVGN-489

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Tevogen Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Tevogen Bio Announces Partnership With BioCentriq to Enhance Tevogen’s Development Capacity of Its Targeted ...

                            Details : Experts from both entities will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 15, 2021

                            Lead Product(s) : TVGN-489

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Tevogen Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.